PURCHASE, NY, April 25, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 (“First Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 (“First Quarter 2023”).
Financial and Operational Highlights for First Quarter 2024
“We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter,” said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. “During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance.”
Key Financial Data | ||||||||||
($ in thousands, except per share data, unaudited) | ||||||||||
Three Months Ended | ||||||||||
March 31, | ||||||||||
2024 | 2023 | Change | ||||||||
Revenue | $ | 646,131 | $ | 629,244 | 3 | % | ||||
Net loss | $ | (81,889 | ) | $ | (69,228 | ) | (18 | )% | ||
Net loss per share, basic and diluted | $ | (0.49 | ) | $ | (0.42 | ) | (17 | )% | ||
Adjusted EBITDA (1) | $ | 63,140 | $ | 52,765 | 20 | % |
See note (1) in the Notes section that follows.
First Quarter 2024
Revenue increased 3% to $646.1 million from $629.2 million in First Quarter 2023. Access fees revenue grew 1% to $557.2 million and other revenue grew 14% to $89.0 million. U.S. revenue grew 1% to $547.6 million and International revenue grew 13% to $98.5 million.
Teladoc Health Integrated Care ("Integrated Care") segment revenue increased 8% to $377.1 million in First Quarter 2024 and BetterHelp segment revenue decreased 4% to $269.0 million.
Net loss totaled $81.9 million, or $0.49 per share, for First Quarter 2024, compared to $69.2 million, or $0.42 per share, for First Quarter 2023. Results for First Quarter 2024 included stock-based compensation expense of $42.3 million, or $0.25 per share, and amortization of acquired intangibles of $64.2 million, or $0.38 per share. The amortization of acquired intangibles increased over the prior year period reflecting a change in the useful lives of certain intangibles in the third quarter of 2023. Net loss for First Quarter 2024 also included $9.7 million, or $0.06 per share, of restructuring costs, primarily related to severance payments.
Results for First Quarter 2023 primarily included stock-based compensation expense of $46.0 million, or $0.28 per share, and amortization of acquired intangibles of $50.3 million, or $0.31 per share. Net loss for First Quarter 2023 also included $8.1 million, or $0.05 per share, of restructuring costs related to the abandonment of certain excess leased office space.
Adjusted EBITDA(1) increased 20% to $63.1 million, compared to $52.8 million for First Quarter 2023. Integrated Care segment adjusted EBITDA increased 36% to $47.7 million in First Quarter 2024 and BetterHelp segment adjusted EBITDA decreased 12% to $15.5 million in First Quarter 2024.
GAAP gross margin, which includes amortization of intangible assets and depreciation of property and equipment, was 65.8% for First Quarter 2024, compared to 67.8% for First Quarter 2023.
Adjusted gross margin(1) was 69.9% for First Quarter 2024, compared to 69.8% for First Quarter 2023.
Capex and Cash Flow
Cash flow from operations was $8.9 million in First Quarter 2024, compared to $13.2 million in First Quarter 2023. Capitalized expenditures and capitalized software development costs (together, “Capex”) was $35.5 million in First Quarter 2024, compared to $45.6 million in First Quarter 2023. Free cash flow was a net outflow of $26.6 million in First Quarter 2024, compared to a net outflow of $32.5 million in First Quarter 2023.
Financial Outlook
Teladoc Health provides an outlook based on current market conditions and expectations and what we know today. Accordingly, we believe our outlook ranges provide a reasonable baseline for future financial performance.
For the second quarter of 2024, we expect:
2Q 2024 Outlook Range | |
Revenue | $635 - $660 million |
Adjusted EBITDA | $70 - $80 million |
Net loss per share | ($0.45) - ($0.35) |
U.S. Integrated Care Members (2) | 92 - 93 million |
Integrated Care | |
Revenue growth percentage (year-over-year) | 2.0% - 5.0% |
Adjusted EBITDA margin | 12.0% - 14.0% |
BetterHelp | |
Revenue growth percentage (year-over-year) | (8.0%) - (4.0%) |
Adjusted EBITDA margin | 9.0% - 10.0% |
For the full year of 2024, we expect:
Full Year 2024 Outlook Range | |
Revenue | $2,635 - $2,735 million |
Adjusted EBITDA | $350 - $390 million |
Net loss per share | ($1.10) - ($0.80) |
Free Cash Flow | $210 - $240 million |
U.S. Integrated Care Members (2) | 92 - 94 million |
Integrated Care | |
Revenue growth percentage (year-over-year) | Low to mid-single digits |
Adjusted EBITDA margin expansion (year-over-year) | +150bps to +250bps |
BetterHelp | |
Revenue growth percentage (year-over-year) | Flat to low single digits |
Adjusted EBITDA margin expansion (year-over-year) | Flat +/- 50bps |
See note (2) in the Notes section that follows.
Three Year Outlook
We are reiterating the three-year outlook that we disclosed in our earnings release on February 20, 2024.
Earnings Conference Call
The First Quarter 2024 earnings conference call and webcast will be held Thursday, April 25, 2024 at 5:00 p.m. E.T. The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 901506. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=60046. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; and (viii) the success of our operational review of the company to achieve a more balanced approach to growth and margin. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
TELADOC HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data, unaudited) | |||||||
Three Months Ended March 31, | |||||||
2024 | 2023 | ||||||
Revenue | $ | 646,131 | $ | 629,244 | |||
Expenses: | |||||||
Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | 194,538 | 190,107 | |||||
Operating expenses: | |||||||
Advertising and marketing | 183,329 | 176,790 | |||||
Sales | 54,364 | 54,490 | |||||
Technology and development | 81,388 | 86,985 | |||||
General and administrative | 111,697 | 114,145 | |||||
Acquisition, integration, and transformation costs | 373 | 5,944 | |||||
Restructuring costs | 9,673 | 8,102 | |||||
Amortization of intangible assets | 95,057 | 66,860 | |||||
Depreciation of property and equipment | 2,834 | 2,923 | |||||
Total expenses | 733,253 | 706,346 | |||||
Loss from operations | (87,122 | ) | (77,102 | ) | |||
Interest income | (13,942 | ) | (8,911 | ) | |||
Interest expense | 5,649 | 5,263 | |||||
Other expense (income), net | 370 | (4,907 | ) | ||||
Loss before provision for income taxes | (79,199 | ) | (68,547 | ) | |||
Provision for income taxes | 2,690 | 681 | |||||
Net loss | $ | (81,889 | ) | $ | (69,228 | ) | |
Net loss per share, basic and diluted | $ | (0.49 | ) | $ | (0.42 | ) | |
Weighted-average shares used to compute basic and diluted net loss per share | 167,730,746 | 162,922,691 |
Stock-based Compensation Summary
Compensation costs for stock-based awards were classified as follows (in thousands):
Three Months Ended March 31, | |||||
2024 | 2023 | ||||
Cost of revenue (exclusive of depreciation and amortization, which are shown separately) | $ | 1,394 | $ | 1,353 | |
Advertising and marketing | 3,789 | 3,126 | |||
Sales | 7,967 | 8,075 | |||
Technology and development | 9,299 | 12,729 | |||
General and administrative | 19,876 | 20,755 | |||
Total stock-based compensation expense (3) | $ | 42,325 | $ | 46,038 |
See note (3) in the Notes section that follows.
Revenues
Three Months Ended | ||||||||
March 31, | ||||||||
($ in thousands, unaudited) | 2024 | 2023 | Change | |||||
Revenue by Type | ||||||||
Access fees | $ | 557,174 | $ | 550,870 | 1 | % | ||
Other | 88,957 | 78,374 | 14 | % | ||||
Total Revenue | $ | 646,131 | $ | 629,244 | 3 | % | ||
Revenue by Geography | ||||||||
U.S. Revenue | $ | 547,600 | $ | 541,662 | 1 | % | ||
International Revenue | 98,531 | 87,582 | 13 | % | ||||
Total Revenue | $ | 646,131 | $ | 629,244 | 3 | % |
Summary Operating Metrics
Consolidated
Three Months Ended | ||||||
March 31, | ||||||
(In millions) | 2024 | 2023 | Change | |||
Total Visits | 4.6 | 4.9 | (6 | )% |
Integrated Care
As of March 31, | ||||||
(In millions) | 2024 | 2023 | Change | |||
U.S. Integrated Care Members (2) | 91.8 | 84.9 | 8 | % | ||
Chronic Care Program Enrollment (4) | 1.121 | 1.028 | 9 | % |
Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | Change | ||||||
Average Monthly Revenue Per U.S. Integrated Care Member (5) | $ | 1.38 | $ | 1.39 | (1 | )% |
BetterHelp
Average for | ||||||
Three Months Ended | ||||||
March 31, | ||||||
(In millions) | 2024 | 2023 | Change | |||
BetterHelp Paying Users (6) | 0.415 | 0.467 | (11 | )% |
See notes (2), (4), (5), and (6) in the Notes section that follows.
Operating Results by Segment (see note (7) in the Notes section that follows)
The following table presents operating results by reportable segment for the periods indicated:
Three Months Ended | ||||||||||
March 31, | ||||||||||
($ in thousands, unaudited) | 2024 | 2023 | Change | |||||||
Teladoc Health Integrated Care | ||||||||||
Revenue | $ | 377,111 | $ | 349,972 | 8 | % | ||||
Adjusted EBITDA | $ | 47,674 | $ | 35,127 | 36 | % | ||||
Adjusted EBITDA Margin % | 12.6 | % | 10.0 | % | 260 bps | |||||
BetterHelp | ||||||||||
Therapy Services | $ | 263,712 | $ | 275,928 | (4 | )% | ||||
Other Wellness Services | 5,308 | 3,344 | 59 | % | ||||||
Total Revenue | $ | 269,020 | $ | 279,272 | (4 | )% | ||||
Adjusted EBITDA | $ | 15,466 | $ | 17,638 | (12 | )% | ||||
Adjusted EBITDA Margin % | 5.7 | % | 6.3 | % | (60) bps |
TELADOC HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited) | |||||||
Three Months Ended March 31, | |||||||
2024 | 2023 | ||||||
Cash flows from operating activities: | |||||||
Net loss | $ | (81,889 | ) | $ | (69,228 | ) | |
Adjustments to reconcile net loss to net cash flows from operating activities: | |||||||
Amortization of intangible assets | 95,057 | 66,860 | |||||
Depreciation of property and equipment | 2,834 | 2,923 | |||||
Amortization of right-of-use assets | 2,614 | 3,056 | |||||
Provision for allowances for doubtful accounts | 86 | 3,794 | |||||
Stock-based compensation | 42,325 | 46,038 | |||||
Deferred income taxes | (1,600 | ) | (355 | ) | |||
Other, net | 1,403 | 3,244 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | 2,133 | (14,046 | ) | ||||
Prepaid expenses and other current assets | (23,691 | ) | (6,165 | ) | |||
Inventory | (3,091 | ) | 10,000 | ||||
Other assets | 1,009 | (9,939 | ) | ||||
Accounts payable | (5,870 | ) | (9,132 | ) | |||
Accrued expenses and other current liabilities | 25,185 | 15,452 | |||||
Accrued compensation | (51,973 | ) | (32,265 | ) | |||
Deferred revenue | 7,297 | 5,648 | |||||
Operating lease liabilities | (2,861 | ) | (2,858 | ) | |||
Other liabilities | (48 | ) | 129 | ||||
Net cash provided by operating activities | 8,920 | 13,156 | |||||
Cash flows from investing activities: | |||||||
Capital expenditures | (1,149 | ) | (2,363 | ) | |||
Capitalized software development costs | (34,363 | ) | (43,261 | ) | |||
Net cash used in investing activities | (35,512 | ) | (45,624 | ) | |||
Cash flows from financing activities: | |||||||
Net proceeds from the exercise of stock options | 131 | 296 | |||||
Proceeds from employee stock purchase plan | 1,516 | 2,731 | |||||
Cash received for withholding taxes on stock-based compensation, net | 106 | 496 | |||||
Other, net | (2 | ) | (170 | ) | |||
Net cash provided by financing activities | 1,751 | 3,353 | |||||
Net decrease in cash and cash equivalents | (24,841 | ) | (29,115 | ) | |||
Effect of foreign currency exchange rate changes | (899 | ) | (488 | ) | |||
Cash and cash equivalents at beginning of the period | 1,123,675 | 918,182 | |||||
Cash and cash equivalents at end of the period | $ | 1,097,935 | $ | 888,579 |
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data, unaudited) | |||||||
March 31, 2024 | December 31, 2023 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 1,097,935 | $ | 1,123,675 | |||
Accounts receivable, net of allowance for doubtful accounts of $3,530 and $4,240 at March 31, 2024 and December 31, 2023, respectively | 214,293 | 217,423 | |||||
Inventories | 32,268 | 29,513 | |||||
Prepaid expenses and other current assets | 141,769 | 118,437 | |||||
Total current assets | 1,486,265 | 1,489,048 | |||||
Property and equipment, net | 29,550 | 32,032 | |||||
Goodwill | 1,073,190 | 1,073,190 | |||||
Intangible assets, net | 1,614,238 | 1,677,781 | |||||
Operating lease - right-of-use assets | 37,506 | 40,060 | |||||
Other assets | 80,007 | 80,258 | |||||
Total assets | $ | 4,320,756 | $ | 4,392,369 | |||
Liabilities and stockholders’ equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 37,674 | $ | 43,637 | |||
Accrued expenses and other current liabilities | 199,418 | 178,634 | |||||
Accrued compensation | 50,523 | 102,686 | |||||
Deferred revenue-current | 101,229 | 95,659 | |||||
Total current liabilities | 388,844 | 420,616 | |||||
Other liabilities | 1,023 | 1,080 | |||||
Operating lease liabilities, net of current portion | 39,971 | 42,837 | |||||
Deferred revenue, net of current portion | 15,002 | 13,623 | |||||
Deferred taxes, net | 47,472 | 49,452 | |||||
Convertible senior notes, net | 1,539,546 | 1,538,688 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Common stock, $0.001 par value; 300,000,000 shares authorized; 169,314,029 shares and 166,658,253 shares issued and outstanding as of March 31, 2024 and December 31, 2023 respectively | 169 | 167 | |||||
Additional paid-in capital | 17,637,902 | 17,591,551 | |||||
Accumulated deficit | (15,310,544 | ) | (15,228,655 | ) | |||
Accumulated other comprehensive loss | (38,629 | ) | (36,990 | ) | |||
Total stockholders’ equity | 2,288,898 | 2,326,073 | |||||
Total liabilities and stockholders’ equity | $ | 4,320,756 | $ | 4,392,369 |
Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we use non-GAAP financial measures to clarify and enhance an understanding of past performance, which include adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA, and free cash flow. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance, and are commonly used by investors to evaluate our performance and that of our competitors. We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business, and that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors, and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows. We use these non-GAAP financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.
Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which are shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue.
EBITDA consists of net loss before interest income; interest expense; other expense (income), net, including foreign currency exchange gains or losses; provision for income taxes; amortization of intangible assets; and depreciation of property and equipment. Adjusted EBITDA consists of net loss before interest income; interest expense; other expense (income), net, including foreign currency exchange gains or losses; provision for income taxes; amortization of intangible assets; depreciation of property and equipment; stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs.
Free cash flow is net cash provided by operating activities less capital expenditures and capitalized software development costs.
Our use of these non-GAAP terms may vary from that of others in our industry, and other companies may calculate such measures differently than we do, limiting their usefulness as comparative measures.
Non-GAAP measures have important limitations as analytical tools and you should not consider them in isolation, and they should not be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other measures derived in accordance with GAAP. Some of these limitations are:
In addition, although amortization of intangible assets and depreciation of property and equipment are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements.
We compensate for these limitations by using these non-GAAP measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.
In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of these non-GAAP measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively:
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin (In thousands, unaudited) | |||||||
Three Months Ended March 31, | |||||||
2024 | 2023 | ||||||
Revenue | $ | 646,131 | $ | 629,244 | |||
Cost of revenue (exclusive of depreciation and amortization, which are shown separately below) | (194,538 | ) | (190,107 | ) | |||
Amortization of intangible assets and depreciation of property and equipment | (26,312 | ) | (12,531 | ) | |||
Gross profit | 425,281 | 426,606 | |||||
Amortization of intangible assets and depreciation of property and equipment | 26,312 | 12,531 | |||||
Adjusted gross profit | $ | 451,593 | $ | 439,137 | |||
Gross margin | 65.8 | % | 67.8 | % | |||
Adjusted gross margin | 69.9 | % | 69.8 | % |
The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to EBITDA and adjusted EBITDA:
Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA (In thousands, except for outlook data, unaudited) | |||||||||||
Outlook in millions (8) | |||||||||||
Three Months Ended March 31, | Second Quarter | Full Year | |||||||||
2024 | 2023 | 2024 | 2024 | ||||||||
Net loss | $ | (81,889 | ) | $ | (69,228 | ) | $(77) - (60) | $(185) - (134) | |||
Add: | |||||||||||
Interest income | (13,942 | ) | (8,911 | ) | |||||||
Interest expense | 5,649 | 5,263 | |||||||||
Other expense (income), net | 370 | (4,907 | ) | ||||||||
Provision for income taxes | 2,690 | 681 | |||||||||
Amortization of intangible assets | 95,057 | 66,860 | |||||||||
Depreciation of property and equipment | 2,834 | 2,923 | |||||||||
Total Adjustments | 92,658 | 61,909 | |||||||||
Consolidated EBITDA | 10,769 | (7,319 | ) | ||||||||
Adjustments: | |||||||||||
Stock-based compensation | 42,325 | 46,038 | |||||||||
Acquisition, integration, and transformation costs | 373 | 5,944 | |||||||||
Restructuring costs | 9,673 | 8,102 | |||||||||
Total Adjustments | 52,371 | 60,084 | 130 - 157 | 484 - 575 | |||||||
Consolidated Adjusted EBITDA | $ | 63,140 | $ | 52,765 | $70 - 80 | $350 - 390 | |||||
Segment Adjusted EBITDA | |||||||||||
Teladoc Health Integrated Care | $ | 47,674 | $ | 35,127 | |||||||
BetterHelp | 15,466 | 17,638 | |||||||||
Consolidated Adjusted EBITDA | $ | 63,140 | $ | 52,765 |
See note (8) in the Notes section that follows.
The following is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP financial measure, to free cash flow:
Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow (In thousands, unaudited) | |||||||||
Three Months Ended | Outlook (9) | ||||||||
March 31, | Full Year | ||||||||
2024 | 2023 | 2024 (in millions) | |||||||
Net cash provided by operating activities | $ | 8,920 | $ | 13,156 | $354 - 374 | ||||
Capital expenditures | (1,149 | ) | (2,363 | ) | |||||
Capitalized software development costs | (34,363 | ) | (43,261 | ) | |||||
Capex | (35,512 | ) | (45,624 | ) | (144) - (134) | ||||
Free cash flow | $ | (26,592 | ) | $ | (32,468 | ) | $210 - 240 |
See note (9) in the Notes section that follows.
Notes:
Investors:
617-444-9612
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Chris Stenrud
860-491-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.97 |
Daily Change: | -0.49 -5.18 |
Daily Volume: | 5,366,761 |
Market Cap: | US$1.540B |
November 25, 2024 October 30, 2024 July 31, 2024 July 16, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB